And this is growing all the time as scientists fro around the...

And this is growing all the time as scientists fro around the globe submit more books for the library.

This is free for PYC because they own the whole family patent. So these peptides are useless to anybody else. So researchers just hand them over, probably for naming rights.

But what should also be mentioned is that Dr Paul WATT also said they know that Small Molecule drugs have a 1 in 10 success rate. The Newer MAB's improve considerably to a 5 in 10 success rate.

However "Phylomers" have a nearly perfect score of 10 out 10 ten.

They fully expect every Phylomer that enters clinical trials to succeed.

Technology and science must have moved along to the point that PYC know this. Seems plausible.

So the next few announcements which are due in next 8 weeks, should highlight this, by the number of targets that are included in each deal.

JANSENN elected five targets and took a six month option to extend to 15 Targets. if the option is picked up, in the next 8 weeks, then the total deals size approaches $3 BN plus royalties on 15 drugs.

As PW said this is the next frontier in medicine, new frontiers don't come along everyday.

So PYC watchers keep a close eye on proceedings, this could bethe tiny bio with the most upside of any. And by the end of this year we should know if this is the case.

Those 500k of oppose at .02 today look like the buy of the year. Good luck to whoever bought them..